捆绑SM社区

MUHC researchers are studying a shorter treatment with fewer side effects.

Patients who are infected with the latent form of tuberculosis (TB) show no symptoms and are not contagious, yet they pose the biggest challenge when it comes to controlling the disease. The latest study by of the Research Institute of the 捆绑SM社区 University Health Centre (MUHC) describes a new potential treatment for this particular form of TB. The paper based on this study was recently published in the Annals of Internal Medicine.

鈥淥ur results show that a four-month treatment with a drug called rifampin is better tolerated than the traditional nine-month treatment with a drug called isoniazid,鈥� explained Dr. Menzies. 鈥淭he side effects with rifampin are much less frequent, particularly liver toxicity - which is the most serious risk of the traditional therapy with isoniazid. In addition patients are much more likely to complete this treatment - another big drawback to the nine month standard therapy.鈥�

Patients who currently receive a diagnosis of latent TB are treated for nine months with daily doses of isoniazid. Although effective, this treatment is very long and has major side effects on the liver. It is therefore common that patients do not complete treatment. Of course, this reduces the treatment鈥檚 efficacy.

The new therapeutic option studied by Dr. Menzies lasts only four months and causes a lot less liver damage. Patients therefore adhere better to their treatment regimens, which is a critical first step towards ensuring the efficacy of the medication. This study was conducted on 847 patients in Canada, Brazil and Saudi Arabia. The results can therefore be generalized to a very broad population.

Currently, rifampin is most often used to treat the active form of TB. More in-depth studies will be necessary to test the effectiveness of this medication against latent TB, but the study researchers consider this treatment option to be very promising.

This study was funded by the Canadian Institutes of Health Research (CIHR) and the Fonds de la recherche en sant茅 du Qu茅bec (FRSQ).

Dr. Dick Menzies is the Director of Respiratory Medicine at the MUHC and a researcher in the Respiratory Health Axis听and Health Outcomes Axis听at the Research Institute of the MUHC. He is also a Professor in Medicine, Epidemiology and Biostatistics - in the Faculty of Medicine of 捆绑SM社区.

The Research Institute of the 捆绑SM社区 Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at 捆绑SM社区 University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.

The Research Institute of the MUHC is supported in part by the Fonds de la recherche en sant茅 du Qu茅bec.

For further details visit: .

Find this press release, with the original article and a short audio document by following this link听:

听